

DAVIS POLK & WARDWELL

1300 I STREET, N.W.
WASHINGTON, D.C. 20005

1600 EL CAMINO REAL
MENLO PARK, CA 94025

99 GRESHAM STREET
LONDON EC2V 7NG

15, AVENUE MATIGNON
75008 PARIS

450 LEXINGTON AVENUE
NEW YORK, N.Y. 10017

212 450 4000
FAX 212 450 3800

WRITER'S DIRECT

212 450 4336

MESSETURM
60308 FRANKFURT AM MAIN

SENADA, 2
RID

NGI
06-6033

.LOAD
HONG KONG




06016582

September 1, 2006

Re: **Submission Pursuant to Rule 12g3-2(b) by Roche Holding Ltd
(File No. 82-3315)**

Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549



SUPPL

Dear Ladies and Gentlemen:

Enclosed please find a copy of certain information concerning transactions in securities of Roche Holding Ltd (File No. 82-3315) published on the website of the Swiss Exchange SWX (www.swx.com/admission/being_public/mtrans/publication_en.html). This information is being furnished to the Securities and Exchange Commission pursuant to Rule 12g3-2(b).

Please do not hesitate to call if you have any questions.

Very truly yours,

Peter R. Douglas

PROCESSED

SEP 08 2006

THOMSON
FINANCIAL

Enclosure



an SWX Group company



Admission

HOME | **ADMISSION** | EXCHANGE TRADING | CLEARING & SETTLEMENT | MARKET DATA | INFORMATION | PARTICIPANTS | ISSUERS | INVESTORS

- Listing
- Admission to trading
- Being Public

- Segments
- Capital market transactions
- Reporting requirements

- Ad hoc publicity
- Financial Reporting
- Disclosure of shareholdings
- Corporate Governance

Management transactions

- Origin
- Legal Basis
- Reporting Engine

Published Notifications

- Privacy Statement

- Contacts
- Contacts

Consultants

- Organisational structure of admission
- Regulation
- Sanctions
- List of Charges
- virt-x
- Contacts

Published Notifications on Management Transactions

The below-mentioned data regarding Management Transactions have been transmitted to the SWX Swiss Exchange by the listed companies. The SWX assumes no liability whatsoever for the completeness, correctness or currentness of this information. Please read our legal notice (disclaimer).

Companies whose securities are admitted to trading in the "EU-Compatible Segment" are subject to the requirements for maintenance of listing that are set out in Art. 23 of the Additional Rules for Listing in the "EU-Compatible" Segment of the SWX. They may therefore report management transactions in accordance with EU as implemented in a given EU member state rather than in accordance with Art. 74a LR. Completed management transactions reported in this manner do not appear on this website.

Transactions from to

Issuer:

Show also corrected notifications

Search and sort:

Occurrences found: **1**
 Locate date: Aug 2006

Issuer	Roche Holding AG
Transaction date	30.08.2006 by an executive member of the board of directors / member of senior management
Type of transaction	Sale of 3'644 securities amounting to CHF 475'167.29312 (CHF 130.40 / security)
Type of security	Equity securities
ISIN	CH0012032048
Further transaction details	Exersale

CONTACT | SEARCH | SITEMAP | DISCLAIMER | PRINT | @ SWX SWISS EXCHANGE



an SWX Group company

Admission

HOME

Listing

Admission to trading

Being Public

Segments

Capital market transactions

Reporting requirements

Ad hoc publicity

Financial Reporting

Disclosure of shareholdings

Corporate Governance

Management transactions

Origin

Legal Basis

Reporting Engine

Published Notifications

Privacy Statement

Contacts

Contacts

Consultants

Organisational structure of admission

Regulation

Sanctions

List of Charges

virt-x

Contacts

ACQUISITION

EXCHANGE TRADING

CLEARING & SETTLEMENT

MARKET DATA

INFORMATION

PARTICIPANTS

ISSUERS

INVESTORS

Published Notifications on Management Transactions

The below-mentioned data regarding Management Transactions have been transmitted to the SWX Swiss Exchange by the listed companies. The SWX assumes no liability whatsoever for the completeness, correctness or currentness of this information. Please refer to our legal notice (disclaimer).

Companies whose securities are admitted to trading in the "EU-Compatible Segment" are subject to the requirements for maintenance of listing that are set out in Art. 23 of the Additional Rules for Listing in the "EU-Compatible" Segment of the SWX. They may therefore report management transactions in accordance with the rules as implemented in a given EU member state rather than in accordance with Art. 74a LR. Completed management transactions reported in this manner do not appear on this website.

Transactions from to

Issuer:

Show also corrected notifications

Search and sort:

Occurrences found: 1

Locate date: Aug 2006

Issuer	Roche Holding AG
Transaction date	30.08.2006 by an executive member of the board of directors / member of senior management
Type of transaction	Sale of 3'644 securities amounting to CHF 475'167.29312 (CHF 130.40 / security)
Type of security	Equity securities
ISIN	CH0012032048
Further transaction details	Exersale


CONTACT SEARCH SITEMAP DISCLAIMER PRINT @SWX SWISS EXCHANGE

Roche - Media News



Media News

Basel, 1 September 2006



International Trade Commission rules in Roche's favour

Mircera case terminated

Roche is pleased to announce that the International Trade Commission in Washington decided not to review its Administrative Law Judge's initial determination to terminate the investigation of the importation of Mircera (a Continuous Erythropoietin Receptor Activator) into the United States. The investigation is ended.

Roche maintains its position that its novel continuous erythropoietin receptor activator does not infringe any of Amgen's U.S. patents for epoetin. The company will continue to focus its efforts on obtaining regulatory approval from U.S. and EU health authorities for Mircera which is in development for the treatment of renal anaemia in chronic kidney disease patients on dialysis and not on dialysis. The US has the largest population worldwide of patients suffering from chronic kidney disease with estimates of 20 million Americans or more.

William M. Burns, CEO Roche Pharma Division, said "The ITC's decision supports our long-term efforts to develop Mircera. We want to offer doctors and patients in the United States the choice of a novel medicine that has been created to allow longer dosing intervals up to every four weeks – something that currently does not exist in the United States. Our energies are focused on continuing our dialogue with health authorities regarding our filings which occurred in April this year and on further clinical trials to manage this oxygen-depriving condition."

About Mircera

Mircera is the first of a new class of anti-anaemia agents called C.E.R.A. (Continuous Erythropoietin Receptor Activator) that represents significant progress in this area. Traditional short-acting erythropoietin-stimulating agents (ESAs) are quickly internalized and degraded after binding to the receptors involved in stimulating red blood cell production. Unlike traditional ESAs Mircera has a greatly reduced affinity to the receptors allowing it to stimulate red cell production without immediate internalization and degradation. This distinct molecular interaction is believed to play a role in providing targeted, stable and sustained control of anaemia. Recently released Phase III data highlighted this new agent's ability to extend dosing intervals up to once monthly while maintaining stable haemoglobin levels in dialysis patients.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of disease, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche

is a world leader in diagnostics, the leading supplier of medicines for cancer and transplantation and a market leader in virology. In 2005 sales by the Pharmaceuticals Division totalled 27.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.2 billion Swiss francs. Roche employs roughly 70,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Additional information about the Roche Group is available on the Internet (www.roche.com).

All trademarks used or mentioned in this release are protected by law.

© 2006 F. Hoffmann-La Roche Ltd

[print close](#)